CERVICAL DISEASE

Findings from 2 studies answer key questions regarding cervical cancer screening. Plus, an explosion of new molecular technology applications has and continues to rapidly expand options for treatment and prevention of cervical cancer.

Mark H. Einstein, MD, MS
Dr. Einstein is Professor and Chair, Department of Obstetrics, Gynecology and Women’s Health, and Assistant Dean, Clinical Research Unit, Rutgers New Jersey Medical School, Newark, New Jersey.

Dr. Einstein has advised, but does not receive an honorarium from any companies. In specific cases his employer has received payment for his consultation from Photocure, Papivax, Inovio, PDS Biotechnologies, Natera, and Immunovaccine. If travel is required for meetings with any industry, the company pays for Dr. Einstein’s travel-related expenses. Also, his employers have received grant funding for research-related costs of clinical trials that Dr. Einstein has been the overall principal investigator or local principal investigator for the past 12 months from Baxalta, Photocure, Fujiboro, Eli Lilly, PDS Biotechnologies, and Becton-Dickinson.

Vaccination against human papillomavirus (HPV) infection and periodic cervical screening have significantly decreased the incidence of invasive cervical cancer. But cancers still exist despite the availability of these useful clinical tools, especially in women of reproductive age in developing regions of the world. In the 2016 update on cervical disease, I reviewed studies on 2 promising and novel immunotherapies for cervical cancer: HPV therapeutic vaccine and adoptive T-cell therapy. This year the focus is on remarkable advances in the field of genomics and related studies that are rapidly expanding our understanding of the molecular characteristics of cervical cancer. Rewards of this research already being explored include novel immunotherapeutic agents as well as the repurposed use of existing drugs.

But first, with regard to cervical screening and follow-up, 2 recent large studies have yielded findings that have important implications for patient management. One pertains to the monitoring of women who have persistent infection with high-risk HPV but cytology results that are negative. Its conclusion was unequivocal and very useful in the management of our patients. The other study tracked HPV screening performed every 3 years and reported on the diagnostic efficiency of this shorter interval screening strategy.

Persistent HPV infection has a higher risk than most clinicians might think


CONTINUED ON PAGE 32

IN THIS
ARTICLE

Persistent HPV infection and CIN page 32
HPV-cytology cotesting page 33
Molecular profiling of cervical cancer page 35

CONTINUED ON PAGE 32
It is well known that most cases of cervical cancer arise from persistent HPV infection, with the highest percentage of cancers caused by high-risk types 16 or 18. What has been uncertain, however, is the actual degree of risk that persistent infection confers over time for the development of cervical intraepithelial neoplasia (CIN) or worse when a woman’s repeated cytology reports are negative. In an analysis of a long-term double-blind, randomized, controlled screening study, Elfgren and colleagues showed that all women whose HPV infection persisted up to 7 years developed CIN grade 2 (CIN2+), while those whose infection cleared in that period, or changed genotype, had no precancerous lesions out to 13 years of follow-up.

Details of the study
Between 1997 and 2000, 12,527 Swedish women between the ages of 32 and 38 years who were undergoing organized cervical cancer screening agreed to participate in a 1:1-randomized prospective trial to determine the benefit of screening with HPV and cytology (intervention group) compared with cytology screening alone (control group). However, brush sampling for HPV was performed even on women in the control group, with the samples frozen for later testing. All participants were identified in the Swedish National Cervical Screening Registry.

Women in the intervention group who initially tested positive for HPV but whose cytology test results were negative (n = 341) were invited to return a year later for repeat HPV testing; 270 women returned and 119 had type-specific HPV persistence. Of those with persistent infection, 100 agreed to undergo colposcopy; 111 women from the control group were randomly selected to undergo sham HPV testing and colposcopy, and 95 attended. Women with evident

FIGURE 1 Implications of HPV infection persistence or clearance for CIN development

All 40 women whose type-specific HPV infection persisted continuously for 7 years (solid line) developed CIN2+. None of the 35 women whose HPV infection cleared or changed genotype developed CIN (dotted line overlapping dash-dot line). Twenty-seven women had unknown HPV persistence status (dashed line).

Abbreviation: CIN, cervical intraepithelial neoplasia; HPV, human papillomavirus.
Cytology is a valuable tool, but it tells us only what is happening today. HPV testing is the crystal ball that tells us a patient’s risk of having a precancerous CIN or cancer in the future. In this well-done randomized prospective trial by Elfgren and colleagues, 100% of women whose persistent HPV infection continued up to 7 years developed CIN2+ or worse. The unmistakable implication of this finding is the need for active follow-up for women with persistent HPV infection. Equally important is the finding that no women who cleared their initial infection developed CIN2+, a very reassuring outcome, and one we can share with patients whose HPV clears.

**WHAT THIS EVIDENCE MEANS FOR PRACTICE**

Cytology is a valuable tool, but it tells us only what is happening today. HPV testing is the crystal ball that tells us a patient’s risk of having a precancerous CIN or cancer in the future. In this well-done randomized prospective trial by Elfgren and colleagues, 100% of women whose persistent HPV infection continued up to 7 years developed CIN2+ or worse. The unmistakable implication of this finding is the need for active follow-up for women with persistent HPV infection. Equally important is the finding that no women who cleared their initial infection developed CIN2+, a very reassuring outcome, and one we can share with patients whose HPV clears.

**FAST TRACK**

Current cervical cancer screening guidelines for 30- to 65-year-old women advise use of cotesting every 3 years or combining HPV testing and cytology every 5 years.

**WHAT THIS EVIDENCE MEANS FOR PRACTICE**

Cytology is a valuable tool, but it tells us only what is happening today. HPV testing is the crystal ball that tells us a patient’s risk of having a precancerous CIN or cancer in the future. In this well-done randomized prospective trial by Elfgren and colleagues, 100% of women whose persistent HPV infection continued up to 7 years developed CIN2+ or worse. The unmistakable implication of this finding is the need for active follow-up for women with persistent HPV infection. Equally important is the finding that no women who cleared their initial infection developed CIN2+, a very reassuring outcome, and one we can share with patients whose HPV clears.

**FAST TRACK**

Current cervical cancer screening guidelines for 30- to 65-year-old women advise use of cotesting every 3 years or combining HPV testing and cytology every 5 years.

**WHAT THIS EVIDENCE MEANS FOR PRACTICE**

Cytology is a valuable tool, but it tells us only what is happening today. HPV testing is the crystal ball that tells us a patient’s risk of having a precancerous CIN or cancer in the future. In this well-done randomized prospective trial by Elfgren and colleagues, 100% of women whose persistent HPV infection continued up to 7 years developed CIN2+ or worse. The unmistakable implication of this finding is the need for active follow-up for women with persistent HPV infection. Equally important is the finding that no women who cleared their initial infection developed CIN2+, a very reassuring outcome, and one we can share with patients whose HPV clears.

**FAST TRACK**

Current cervical cancer screening guidelines for 30- to 65-year-old women advise use of cotesting every 3 years or combining HPV testing and cytology every 5 years.

**WHAT THIS EVIDENCE MEANS FOR PRACTICE**

Cytology is a valuable tool, but it tells us only what is happening today. HPV testing is the crystal ball that tells us a patient’s risk of having a precancerous CIN or cancer in the future. In this well-done randomized prospective trial by Elfgren and colleagues, 100% of women whose persistent HPV infection continued up to 7 years developed CIN2+ or worse. The unmistakable implication of this finding is the need for active follow-up for women with persistent HPV infection. Equally important is the finding that no women who cleared their initial infection developed CIN2+, a very reassuring outcome, and one we can share with patients whose HPV clears.
Analyzing data from >1 million women, Silver and colleagues found that 3-year HPV-cytology cotesting safely lowered population rates of cervical precancer and cancer.

Details of the study

Included were all women 30 years of age or older enrolled in this study at KPNC between 2003 and 2012 who underwent HPV–cytology cotesting every 3 years. The population in its entirety (1,065,273 women) was deemed the “open cohort” and represented KPNC’s total annual experience. A subset of this population, the “closed cohort,” was designed to gauge the effect of repeated screening on a fixed population and comprised only those women enrolled and initially screened between 2003 and 2004 and then followed longitudinally until 2012.

For each cohort, investigators calculated the ratios of precancer and cancer diagnoses to the total number of cotests performed on the cohort’s population. The 3-year testing periods were 2004–2006, 2007–2009, and 2010–2012. Also calculated in these periods were the ratios of colposcopic biopsies to cotests and the rates of precancer diagnoses (TABLE).

In the open cohort, the biopsy rate nearly doubled over the course of the study. Precancer diagnoses per number of cotests rose by 71.5% between the first and second testing periods (P= .001) and then eased off by 10% in the third period (P<.001). These corresponding increases throughout the study yielded a stable number of biopsies (16 to 22) needed to detect precancer.

In the closed long-term cohort, the biopsy rate rose, but not as much as in the

FAST TRACK

WHAT THIS EVIDENCE MEANS FOR PRACTICE

Patients are dissatisfied with the 5-year screening interval for cotesting, and many of them wish to return to shorter interval testing. What this large-scale study shows is that 3-year cotesting safely lowers population rates of cervical precancer and cancer and does so at an interval that should help ease patients’ minds.
open cohort. Precancer diagnoses per number of cotests rose by 47% between the first and second periods ($P\leq.001$), but in the third period fell back by 28% ($P<.001$) to a level just above the first period results. The number of biopsies needed to detect a precancerous lesion in the closed cohort rose from 19 to 33 over the course of the study, suggesting there may have been some loss of screening efficiency in the fixed group.

Molecular profiling of cervical cancer is revolutionizing treatment

Effective treatments for cervical cancer could be close at hand, thanks to a recent explosion of knowledge at the molecular level about how specific cancers arise and what drives them other than HPV. The Cancer Genome Atlas Research Network (TCGA) recently published the results of its genomic and proteomic analyses, which yielded distinct profiles for 178 cervical cancers with important patterns common to other cancers, such as uterine and breast cancer. These recently published findings on cervical cancer highlight areas of gene and protein dysfunction it shares with these other cancers, which could open the doors for new targets for treatments already developed or in the pipeline.

How molecular profiling is paying off for cervical cancer

Cancers develop in any given tissue through the altered function of different genes and signaling pathways in the tissue’s cells. The latest extensive investigation conducted by the TCGA network has identified significant mutations in 5 genes previously unrecognized in association with cervical cancer, bringing the total now to 14.

Several highlights are featured in the TCGA’s recently published work. One discovery is the amplification of genes CD274 and PDCD1LG2, which are involved with the expression of 2 cytolytic effector genes and are therefore likely targets for immunotherapeutic strategies. Another line of exploration, whole-genome sequencing, has detected an aberration in some cervical cancer tissue with the potential for immediate treatment.

FIGURE 2 The Cancer Genome Atlas Research Network

The Cancer Genome Atlas Research Network (TCGA) is integrating data obtained from molecular-level tumor tissue analyses, such as DNA mutation and methylation, messenger- and micro-RNA expression, gene copy number variations, and reverse phase protein arrays to generate molecular profiles of clinical tumors and their subtypes. These profiles combined with clinical data are leading to novel molecular therapeutic strategies and prognostic indicators that increase the precision and effectiveness of cancer treatment. Using this multiparametric analytic approach, the TCGA has identified and profiled more than 200 types of cervical cancer.

application. Duplication and copy number gain of BCAR4, a noncoding RNA, facilitates cell proliferation through the HER2/HER3 pathway, a target of the tyrosine-kinase inhibitor, lapatinib, which is currently used to treat breast cancer.

The integration of data from multiple layers of analysis (FIGURE 2, page 35) is helping investigators identify variations in cancers. DNA methylation, for instance, is a means by which cells control gene expression. An analysis of this process in cervical tumor tissue has revealed additional cancer subgroups in which messenger RNA increases the transition of epithelial cells to invasive mesenchymal cells. Targeting that process in these subgroups would likely enhance the effectiveness of novel small-molecule inhibitors and some standard cytotoxic chemotherapy.

WHAT THIS EVIDENCE MEANS FOR PRACTICE

It is this kind of detailed molecular knowledge—that is far more clinically meaningful than information provided by standard histology—that will 1) define cancer typing at a more precise level, 2) guide the development of targeted individualized treatments, and 3) give new hope to patients with aggressive cancers. While much of the malignant transformation is HPV driven, other genetic patterns can be targeted. Therapeutic investigation is now moving forward, focusing on the recently revealed similarities between cancers in different parts of the body. The National Cancer Institute, in conjunction with clinical partners across the country, is enrolling patients with different tumor types in its NCI-MATCH (Molecular Analysis for Therapy Choice) trial. In brief, patients who have a tumor (regardless of origin or tissue type) containing specific molecular abnormalities already recognized in another cancer and targeted by an existing drug will receive that treatment to determine if it will prove effective.

For more information, visit the NCI-MATCH website: https://www.cancer.gov/about-cancer/treatment/clinical-trials/nci-supported/nci-match.

References